Prediction of homologous recombination deficiency identifies colorectal tumors sensitive to PARP inhibition

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: 1 Online-Ressource.

Language: Englisch

Bibliographic citation: Prediction of homologous recombination deficiency identifies colorectal tumors sensitive to PARP inhibition ; volume:8 ; number:1 ; day:14 ; month:10 ; year:2024 ; pages:1-9 ; date:12.2024
npj precision oncology ; 8, Heft 1 (14.10.2024), 1-9, 12.2024

Creator: Corti, Giorgio
Buzo, Kristi
Berrino, Enrico
Miotto, Martina
Aquilano, Maria Costanza
Lentini, Marilena
Bellomo, Sara Erika
Lorenzato, Annalisa
Bartolini, Alice
Mauri, Gianluca
Lazzari, Luca
Russo, Mariangela
Nicolantonio, Federica Di
Siena, Salvatore
Marsoni, Silvia
Marchiò, Caterina
Bardelli, Alberto
Arena, Sabrina

Contributor: SpringerLink (Online service)

DOI: 10.1038/s41698-024-00706-7

URN: urn:nbn:de:101:1-2501012102560.374946180247

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:32 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Corti, Giorgio
Buzo, Kristi
Berrino, Enrico
Miotto, Martina
Aquilano, Maria Costanza
Lentini, Marilena
Bellomo, Sara Erika
Lorenzato, Annalisa
Bartolini, Alice
Mauri, Gianluca
Lazzari, Luca
Russo, Mariangela
Nicolantonio, Federica Di
Siena, Salvatore
Marsoni, Silvia
Marchiò, Caterina
Bardelli, Alberto
Arena, Sabrina
SpringerLink (Online service)

Other Objects (12)

Homologous Recombination Deficiency Unrelated to Platinum and PARP Inhibitor Response in Cell Line Libraries

Homologous recombination deficiency in breast cancer

PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer

Correlation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agents

Leveraging homologous recombination repair deficiency in sarcoma

Targeting homologous recombination deficiency in uterine leiomyosarcoma

Homologous recombination deficiency in epithelial ovarian cancer

Pan-cancer landscape of homologous recombination deficiency

ATR, CHK1 and WEE1 inhibitors cause homologous recombination repair deficiency to induce synthetic lethality with PARP inhibitors

Functional RECAP (REpair CAPacity) assay identifies homologous recombination deficiency undetected by DNA-based BRCAness tests

PLK1 overexpression suppresses homologous recombination and confers cellular sensitivity to PARP inhibition

Multi-scale characterisation of homologous recombination deficiency in breast cancer

Homologous Recombination Deficiency Unrelated to Platinum and PARP Inhibitor Response in Cell Line Libraries

Homologous recombination deficiency in breast cancer

PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer

Correlation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agents

Leveraging homologous recombination repair deficiency in sarcoma

Targeting homologous recombination deficiency in uterine leiomyosarcoma

Homologous recombination deficiency in epithelial ovarian cancer

Pan-cancer landscape of homologous recombination deficiency

ATR, CHK1 and WEE1 inhibitors cause homologous recombination repair deficiency to induce synthetic lethality with PARP inhibitors

Functional RECAP (REpair CAPacity) assay identifies homologous recombination deficiency undetected by DNA-based BRCAness tests

PLK1 overexpression suppresses homologous recombination and confers cellular sensitivity to PARP inhibition

Multi-scale characterisation of homologous recombination deficiency in breast cancer

Homologous Recombination Deficiency Unrelated to Platinum and PARP Inhibitor Response in Cell Line Libraries

Homologous recombination deficiency in breast cancer

PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer

Correlation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agents

Leveraging homologous recombination repair deficiency in sarcoma

Targeting homologous recombination deficiency in uterine leiomyosarcoma

Homologous recombination deficiency in epithelial ovarian cancer

Pan-cancer landscape of homologous recombination deficiency

ATR, CHK1 and WEE1 inhibitors cause homologous recombination repair deficiency to induce synthetic lethality with PARP inhibitors

Functional RECAP (REpair CAPacity) assay identifies homologous recombination deficiency undetected by DNA-based BRCAness tests

PLK1 overexpression suppresses homologous recombination and confers cellular sensitivity to PARP inhibition

Multi-scale characterisation of homologous recombination deficiency in breast cancer

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Prediction of homologous recombination deficiency identifies colorectal tumors sensitive to PARP inhibition

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Homologous Recombination Deficiency Unrelated to Platinum and PARP Inhibitor Response in Cell Line Libraries

Homologous recombination deficiency in breast cancer

PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer

Correlation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agents

Leveraging homologous recombination repair deficiency in sarcoma

Targeting homologous recombination deficiency in uterine leiomyosarcoma

Homologous recombination deficiency in epithelial ovarian cancer

Pan-cancer landscape of homologous recombination deficiency

ATR, CHK1 and WEE1 inhibitors cause homologous recombination repair deficiency to induce synthetic lethality with PARP inhibitors

Functional RECAP (REpair CAPacity) assay identifies homologous recombination deficiency undetected by DNA-based BRCAness tests

PLK1 overexpression suppresses homologous recombination and confers cellular sensitivity to PARP inhibition

Multi-scale characterisation of homologous recombination deficiency in breast cancer

Homologous Recombination Deficiency Unrelated to Platinum and PARP Inhibitor Response in Cell Line Libraries

Homologous recombination deficiency in breast cancer

PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer

Correlation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agents

Leveraging homologous recombination repair deficiency in sarcoma

Targeting homologous recombination deficiency in uterine leiomyosarcoma

Homologous recombination deficiency in epithelial ovarian cancer

Pan-cancer landscape of homologous recombination deficiency

ATR, CHK1 and WEE1 inhibitors cause homologous recombination repair deficiency to induce synthetic lethality with PARP inhibitors

Functional RECAP (REpair CAPacity) assay identifies homologous recombination deficiency undetected by DNA-based BRCAness tests

PLK1 overexpression suppresses homologous recombination and confers cellular sensitivity to PARP inhibition

Multi-scale characterisation of homologous recombination deficiency in breast cancer

Homologous Recombination Deficiency Unrelated to Platinum and PARP Inhibitor Response in Cell Line Libraries

Homologous recombination deficiency in breast cancer

PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer

Correlation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agents

Leveraging homologous recombination repair deficiency in sarcoma

Targeting homologous recombination deficiency in uterine leiomyosarcoma

Homologous recombination deficiency in epithelial ovarian cancer

Pan-cancer landscape of homologous recombination deficiency

ATR, CHK1 and WEE1 inhibitors cause homologous recombination repair deficiency to induce synthetic lethality with PARP inhibitors

Functional RECAP (REpair CAPacity) assay identifies homologous recombination deficiency undetected by DNA-based BRCAness tests

PLK1 overexpression suppresses homologous recombination and confers cellular sensitivity to PARP inhibition

Multi-scale characterisation of homologous recombination deficiency in breast cancer

Related objects

Reset password